PRRT with or without chemotherapy for GEP NET
Part of Cancer clinical trials.
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a well-differentiated neuroendocrine tumor of the digestive tract or pancreas (GEP NET).
- Your tumor is either grade 2 or 3 (with specific cell growth rates) or grade 1 but has worsened in the last 6 months.
- Your tumor shows high activity on both a special PET scan (Ga-68 DOTANOC) and an FDG PET scan.
- Your tumor cannot be removed by surgery or has spread to other parts of the body.
- You are generally healthy enough for treatment (performance status score 60 or above).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This trial combines external radiation with a targeted radioactive drug (PRRT) to treat large, slow-growing neuroendocrine tumors in the gut that have spread and are not removable by surgery. It aims to see if this combination works better than either treatment alone.
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
Hear when a new Neuroendocrine Neoplasia's (NENs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.